About Pliant Therapeutics Inc.

Pliant Therapeutics Inc., founded in 2015, emerged from pioneering research in understanding the fundamental mechanisms of tissue fibrosis, a process underlying many chronic and life-threatening diseases. The company was established by leading fibrosis researchers who recognized the opportunity to develop targeted therapies for fibrotic diseases that currently have limited treatment options. PLRX stock price reflects investor interest in the company's innovative approach to addressing large markets with significant unmet medical needs in fibrotic diseases.

Under the leadership of CEO Bernard Coulie, MD, PhD, who brings extensive drug development experience from major pharmaceutical companies, Pliant has assembled a world-class team of scientists and drug developers. The management team combines deep expertise in fibrosis biology with proven track records in advancing novel therapeutics through clinical development. Leadership's strategic focus on building a robust pipeline and establishing partnerships has been instrumental in advancing programs and creating value that impacts PLRX stock price movement.

Pliant Therapeutics operates a fully integrated drug discovery and development platform focused on targeting key drivers of fibrosis across multiple organ systems. The company's lead programs target idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), with additional programs addressing fibrotic diseases of the liver, kidney, and other organs. With a differentiated approach targeting specific integrin pathways involved in fibrosis progression and multiple clinical programs advancing through development, PLRX offers investors exposure to the large and growing fibrotic disease therapeutics market where successful treatments can address significant unmet needs and command premium pricing.